The Senate’s long-awaited movement on the critical issue of insulin affordability marks a pivotal step forward for patients. However, lawmakers must thoroughly scrutinize the additional healthcare measures that may be included in the bill. Specifically, the Pharmacy Benefit Manager Reform Act, currently under consideration, has the potential to exacerbate the very problem the insulin measure seeks to solve by driving up drug prices across the board.
Proposed by Sen. Bernie Sanders, this provision, if enacted, would burden Alabama families with skyrocketing drug costs, undermining the bill’s objective of making essential medications more affordable.
Senators Katie Britt and Tommy Tuberville are rightly working to address insulin prices, given that the state has the fifth-highest percentage of adults with diabetes, with roughly half a million patients in the state ready to benefit from a cap on insulin prices.
But adding the Pharmacy Benefit Manager Reform Act to the overall package will do more harm than good, and I urge our senators to firmly oppose the inclusion of this act.
Pharmacy Benefit Managers (PBMs) serve as a crucial pillar of our healthcare system, saving Americans an average of over $1,000 per year on prescription drug costs. Operating as private sector negotiators, they hold pharmaceutical companies accountable and effectively drive down prices through strategic measures such as rebates, specialty pharmacies, and mail-order services, among others.
By leveraging their extensive networks, PBMs negotiate to provide employers and insurers with a variety of coverage choices and flexibility, which translates into more affordable and quality prescription coverage for patients. This means that individuals can enjoy the benefits of affordable medications while health plans can allocate their resources more efficiently, creating a win-win situation for all.
Without the negotiating power of PBMs, Americans will be left at the mercy of Big Pharma’s relentless mission to increase profits. Alabamians cannot afford to jeopardize the hard-won cost savings and consumer choice that PBMs provide.
Equally concerning, this legislation would reduce employer flexibilities, which would have dire consequences.
The Pharmacy Benefit Manager Reform Act will not only lead to skyrocketing pharmaceutical prices but also pave the way for increased government interference in healthcare – a long-time goal of Sen. Sanders. Such proposals further regulating PBMs will give the government increased control over the healthcare system. This heavy-handed approach jeopardizes individual liberty, free market competition, and choice, undermining the foundations of our healthcare system.
While the Senate’s focus on insulin affordability is crucial—an issue Sens. Britt and Tuberville made a priority in the upper chamber—they must also assess the negative impact of the addition of the PBM legislation. This amendment could prove to be a poison pill. By avoiding hasty decisions and taking a thoughtful and measured approach, we can achieve meaningful and sustainable healthcare reform that benefits all Americans.
It is crucial for Congress to recognize the invaluable role that PBMs play in driving down prices, preserving consumer choice, and ensuring affordable healthcare for all. Otherwise, Alabama patients will find themselves paying more for life-saving medication.
CJ Pearson is a conservative activist and University of Alabama graduate.
